Effects of Ketoconazole on the Pharmacokinetics of Ponatinib in Healthy Subjects

Ponatinib is a BCR-ABL tyrosine kinase inhibitor (TKI) approved for the treatment of chronic myeloid leukemia and Philadelphia chromosome–positive acute lymphoblastic leukemia in patients resistant or intolerant to prior TKIs. In vitro studies suggested that metabolism of ponatinib is partially medi...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Narasimhan, Narayana I, Dorer, David J, Niland, Katie, Haluska, Frank, Sonnichsen, Daryl
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Blackwell Publishing Ltd 2013
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3781849/
https://ncbi.nlm.nih.gov/pubmed/23801357
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.109
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak